**Supplementary Table S3.** Univariate analysis of overall survival by Cox proportional hazards regression model

|  |  |  |
| --- | --- | --- |
|  | **HR for death** **(95% C.I.)** | **p** |
| Standard vs. Non-standard group  | 6.9 (2.1 – 22.9) | 0.002 |
| Age (years) | 1.0 (0.9 – 1.1) | 0.060 |
| Never vs. current/former smoker  | 1.5 (0.6 – 4.0) | 0.85 |
| ECOG PS ≥ 2 vs. 0-1 | 1.8 (0.8 – 3.9) | 0.175 |
| <50% vs. ≥ 50% PD-L1 TPS  | 1.4 (0.7 – 2.9) | 0.90 |
| Later vs. first line of therapy | 0.5 (0.2 – 1.3) | 0.167 |
| Pembrolizumab alone vs. along with chemotherapy | 1.0 (0.5 – 2.1) | 0.944 |
| No. of treatment cycles | 0.8 (0.7 – 0.9) | <0.001 |
| Absence vs. presence of any grade irAE | 2.2 (1.1 – 4.5) | 0.030 |
| VMC vs. BIDMC | 0.8 (0.4 – 1.7) | 0.615 |

Abbreviations: HR, hazard ratio; C.I., confidence intervals; TPS, tumor proportion score; ECOG, Eastern Cooperative Oncology Group; PS, performance status; irAE, immune-related adverse events.